+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H1 2019

  • ID: 4778167
  • Drug Pipelines
  • June 2019
  • Region: Global
  • 58 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Eisai Co Ltd
  • Eli Lilly and Co
  • GlaxoSmithKline Plc
  • Ono Pharmaceutical Co Ltd
  • RaQualia Pharma Inc
  • Rottapharm Biotech Srl
  • MORE
Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H1 2019

Summary

According to the recently published report 'Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H1 2019'; Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function.

The report 'Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H1 2019' outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 1, 6 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Immunology, Women's Health, Gastrointestinal, Metabolic Disorders and Respiratory which include indications Lung Cancer, Breast Cancer, Colon Cancer, Endometriosis, Inflammatory Pain, Liver Cancer, Pain, Prostate Cancer, Allergies, Arthritis Pain, Autoimmune Disorders, Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Esophageal Cancer, Familial Adenomatous Polyposis, Gastric Cancer, Gastrointestinal Tract Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Osteoarthritis Pain, Osteogenesis Imperfecta, Osteoporosis, Post-Operative Pain, Rectal Cancer, Rheumatoid Arthritis, Solid Tumor and Ulcerative Colitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
  • The report reviews Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Eisai Co Ltd
  • Eli Lilly and Co
  • GlaxoSmithKline Plc
  • Ono Pharmaceutical Co Ltd
  • RaQualia Pharma Inc
  • Rottapharm Biotech Srl
  • MORE
Introduction

Report Coverage

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Overview

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Companies Involved in Therapeutics Development

Eisai Co Ltd

Eli Lilly and Co

GlaxoSmithKline Plc

Kaken Pharmaceutical Co Ltd

Ono Pharmaceutical Co Ltd

RaQualia Pharma Inc

Rottapharm Biotech Srl

Tempest Therapeutics Inc

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drug Profiles

AAT-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARTEP - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CR-6086 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-7046 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

grapiprant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-726701A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KAG-308 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-4578 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RMX-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize EP4 Receptor for Osteoporosis and Osteogenesis Imperfecta - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize EP4 Receptor for Inflammatory Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize EP2 and EP4 Receptor for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Dormant Products

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Discontinued Products

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Product Development Milestones

Featured News & Press Releases

May 07, 2019: Kyn Therapeutics strengthens leadership team with key appointments

Dec 20, 2018: Kyn Therapeutics and Merck begin Phase Ib/I trials of ARY-007

Jul 19, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Is Approved in China

Apr 17, 2018: Japan Patent Office Granted AskAt a Cartilage Disease Use Patent of EP4 Antagonist

Jan 22, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in China

Jan 22, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in China

Dec 18, 2017: Investigational new drug application for EP4 antagonist AAT-007 was approved by the National Food and Drug Administration of the People's Republic of China

Sep 01, 2017: Autoimmune disease Use Patent for EP4 antagonist Approved in Korea

Sep 01, 2017: Eisai to Present Abstract on E7046 at ESMO 2017 Congress

Sep 01, 2017: Eisai to Present Abstract on its Oncology Product Candidate E7046 at the ESMO 2017 Congress

Jun 30, 2017: India Patent Office Granted AskAt a Substance Patent of EP4 antagonist(AAT-007)

Apr 25, 2017: Autoimmune disease Use Patent for EP4 antagonist Approved in Japan

Mar 30, 2017: Treatment of Cancer Use Patent for EP4 antagonist Approved in US

Aug 17, 2016: Treatment of Cancer Use Patent for EP4 antagonist Approved in China

Jun 03, 2016: Autoimmune disease Use Patent for EP4 antagonist Approved in Mexico

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indications, H1 2019

Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019 (Contd..2), H1 2019

Number of Products under Investigation by Universities/Institutes, H1 2019

Products under Investigation by Universities/Institutes, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by Eisai Co Ltd, H1 2019

Pipeline by Eli Lilly and Co, H1 2019

Pipeline by GlaxoSmithKline Plc, H1 2019

Pipeline by Kaken Pharmaceutical Co Ltd, H1 2019

Pipeline by Ono Pharmaceutical Co Ltd, H1 2019

Pipeline by RaQualia Pharma Inc, H1 2019

Pipeline by Rottapharm Biotech Srl, H1 2019

Pipeline by Tempest Therapeutics Inc, H1 2019

Dormant Projects, H1 2019

Discontinued Products, H1 2019

Discontinued Products, H1 2019 (Contd..1), H1 2019

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Eisai Co Ltd
  • Eli Lilly and Co
  • GlaxoSmithKline Plc
  • Kaken Pharmaceutical Co Ltd
  • Ono Pharmaceutical Co Ltd
  • RaQualia Pharma Inc
  • Rottapharm Biotech Srl
  • Tempest Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll